Assessment of Liver Function

Sherlock's Diseases of the Liver and Biliary System, 12th Edition

Volumn , Issue , 2011, Pages 20-35

  Mukherjee, Sandeep ^a   Gollan, John L ^b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Ageing; Ammonia; Carbohydrate; Cholestatic; Enzyme; Hepatocellular; Infiltrative; Jaundice; Lipid; Protein

Indexed keywords

EID: 84888041493     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341294.ch2     Document Type: Chapter

References (71)

1. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the esophagus for bleeding esophageal varices. Br. J. Surg. 1973; 60: 646-649.
2. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
3. Imperial JC, Keeffe EB. Laboratory tests. In: Bacon BR, O'Grady JG, Di Biscceglie AM, Lake JR, eds. Comprehensive Clinical Hepatology, 2nd edn. Philadelphia: Elsevier Mosby, 2006, p. 79.
4. den Bergh AAH, Muller P. Uber eine und eine indirekte Diazoreaktion auf Bilirubin. Biochem. Z. 1916; 77: 90.
5. Tiribelli C, Ostrow JD. New concepts in bilirubin and jaundice: report of the Third International Bilirubin Workshop, April 6-8, 1995, Trieste, Italy. Hepatology 1996; 24: 1296-1311.
6. Fevery J, Blanckaert N. What can we learn from analysis of serum bilirubin? J. Hepatol. 1986; 2: 113-121.
7. Binder L, Smith D, Kupka T et al. Failure of prediction of liver function test abnormalities with the urine urobilinogen and urine bilirubin assays. Arch. Pathol. Lab. Med. 1989; 113: 73-76.
8. Kubitz R, Wettstein M, Warskulat U et al. Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone. Gastroenterology 1999; 116: 401-410.
9. Mandema E, DeFraiture WH, Niewig HO et al. Familial chronic idiopathic jaundice (Dubin-Sprinz disease) with a note on bromsulphalein metabolism in this disease. Am. J. Med. 1960; 28: 42-50.
10. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 1-10.
11. Jamjute P, Ahmad A, Ghosh T et al. Liver function test and pregnancy. J. Matern. Fetal Neonatal Med. 2009; 22: 274-283.
12. Caropreso M, Fortunato G, Lenta S et al. Prevalence and long-term course of macro-aspartate aminotransferase in children. J. Pediatr. 2009; 154: 744-748.
13. Fabrizi F, Lunghi G, Finazzi S et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am. J. Kidney Dis. 2001; 38: 1009-1015.
14. Allman MA, Pang E, Yau DF et al. Elevated plasma vitamers of vitamin B6 in patients with chronic renal failure in regular hemodialysis. Eur. J. Clin. Nutr. 1992; 46: 679-683.
15. Price CP, Alberti KGMM. Biochemical assessment of liver function. In: Wright R, Alberti KGMM, Karran S, Millward-Sadler GH, eds. Liver and Biliary Disease-Pathophysiology, Diagnosis and Managemement. London: W.B.Saunders, 1979, p. 381-416.
16. Rizvi AA, Kerrick JG. Liver involvement and abnormal iron variables in undiagnosed Addison's disease. Endocr. Pract. 2001; 7: 184-188.
17. Fong HF, Divasta AD, Difabio D et al. Prevalence and predictors of abnormal liver enzymes in young women with anorexia nervosa. J. Pediatr. 2008; 153: 247-253.
18. Volta U, Granito A, De Franceschi L et al. Anti-tissue transglutaminase antibodies as predictors of silent coeliac disease in patients with hypertransaminasaemia of unknown origin. Dig. Liver Dis. 2001; 33: 420-425.
19. Kubota S, Amino N, Matsumoto Y et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves'disease and painless thyroiditis. Thyroid 2008; 18: 283-287.
20. Whitehead MW, Hawkes ND, Hainsworth I et al. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 1999; 45: 129-133.
21. Ludwig S, Kaplowitz N. Effect of serum pyridoxine defi-ciency on serum and liver transaminases in experimental liver injury in the rat. Gastroenterology 1980; 79: 545-549.
22. Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
23. Giannini E, Risso D, Botta F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch. Intern. Med. 2003; 163: 218-224.
24. Weiss MJ, Ray K, Henthorn PS et al. Structure of the human liver/bone/kidney alkaline phosphatase gene. J. Biol. Chem. 1988; 263: 12002-12010.
25. Nakano T, Shimanuki T, Matsushita M et al. Involvement of intestinal alkaline phosphatase in serum apolipoprotein B-48 level and its association with ABO and secretor blood group types. Biochem. Biophys. Res. Commun. 2006; 341: 33-38.
26. Maldonado O, Demasi R, Maldonado Y et al. Extremely high levels of alkaline phosphatase in hospitalized patients. J. Clin. Gastroenterol. 1998; 27: 342-345.
27. O'Leary JG, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 2007; 23: 232-236.
28. Cassidy WM, Reynolds TB. Serum lactic acid dehydrogenase in the differential diagnosis of acute hepatocellular injury. J. Clin. Gastroenterol. 1994; 19: 118-121.
29. Zucker SD, Gollan JL. Physiology of the liver. In: Haubrich WS, Schaffner F, Berk JE, eds. Bockus Gastroenterology, 5th edn. Philadelphia: Wiley Saunders, 1995, p. 1858-1905.
30. Jonas A. Lecithin cholesterol acyl transferase. Biochim. Biophys. Acta. 2000; 1529: 245-256.
31. Oude Elferink RP, Groen AK. Mechanisms of biliary lipid secretion and their role in lipid homeostasis. Semin. Liv. Dis. 2002; 20: 293-305.
32. Crawford JM, Mockel GM, Crawford AR et al. Imaging biliary lipid secretion in the rat: ultrastructural evidence for vesiculation of the hepatocyte canalicular membrane. J. Lipid Res. 1995; 36: 2147-2163.
33. Mansbach CM 2nd, Gorelick F. Dietary lipid absorption, complex lipid synthesis and intracellular packaging and secretion of chylomicrons. Am. J. Physiol. Gastrointest. Liver Physiol. 2007; 293: G645-650.
34. Williams KJ. Molecular processes that handle-and mishandle -dietary lipids. J. Clin. Invest. 2008; 118: 3247-3259.
35. Wade DP, Owen JS. Regulation of the cholesterol efflux gene, ABCA1. Lancet 2001; 357: 161-163.
36. Solaymani-Dodaran M, Aithal GP, Card T et al. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am. J. Gastroenterol. 2008; 103: 2784-2788.
37. Mirandola S, Realdon S, Iqbal J et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 2006; 130: 1661-1669.
38. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin. Liver Dis. 2007; 27: 44-54.
39. Sacks FM. The apolipoprotein story. Atherosclerosis 2006; 7 (Suppl.): 23-27.
40. Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell. Mol. Life Sci. 2005; 62: 2150-2156.
41. Hofmann AF. Bile acids-trying to understand their chemistry and biology with the hope of helping patients. Hepatology 2009; 49: 1403-1418.
42. Pikuleva IA. Cytochrome P450s and cholesterol homeostasis. Pharmacol. Ther. 2006; 112: 761-773.
43. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006; 3: 318-328.
44. Stiehl A, Raedsch R, Rudolph G. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids. Gastroenterology 1990; 98: 424-428.
45. Wolkoff AW, Cohen DE. Bile acid regulation of hepatic physiology: I. Hepatocyte transport of bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 2003; 284: G175-179.
46. Takikawa H. Hepatobiliary transport of bile acids and organic anions. J. Hepatobiliary Pancreat. Surg. 2002; 9: 443-447.
47. Sturm E, Wagner M, Trauner M. Nuclear receptor ligands in therapy of cholestatic liver disease. Front. Biosci. 2009; 14: 4299-4325.
48. Carulli N, Bertolotti M, Carubbi F et al. Review article: effect of bile salt pool composition on hepatic and biliary functions. Aliment. Pharmacol. Ther. 2000; 14: 14-18.
49. Robb BW, Matthews JB. Bile salt diarrhea. Curr. Gastroenterol. Rep. 2005; 7: 379-383.
50. Moseley RH. Hepatic amino acid transport. Semin. Liver Dis. 1996; 16: 137-145.
51. Morgan MY, Marshall AW, Milsom JP et al. Plasma amino-acid patterns in liver disease. Gut 1982; 23: 362-370.
52. Clemmesen JO, Larsen FS, Kondrup J et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1994; 29: 648-653.
53. Tavill AS. The synthesis and degradation of liver-produced proteins. Gut 1972; 13: 225-241.
54. Sehgal PB. Interleukin-6: a regulator of plasma protein gene expression in hepatic and nonhepatic tissues. Mol. Biol. Med. 1990; 7: 117-130.
55. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991; 13: 364-375.
56. Tavill AS, Craigie A, Rosenoer VM. The measurement of the synthetic rate of albumin in man. Clin. Sci. 1968; 34: 1-28.
57. Ballmer PE, Reichen J, McNurlan MA et al. Albumin but not fibrinogen synthesis correlates with galactose elimination capacity in patients with cirrhosis of the liver. Hepatology 1996; 24: 53-59.
58. Barle H, Nyberg B, Essen P et al. The synthesis rates of total liver protein and plasma albumin determined simultaneously in vivo in humans. Hepatology 1997; 25: 154-158.
59. Robert A, Chazouillères O. Prothrombin time in liver failure: time, ratio, activity percentage or International Normalized Ratio. Hepatology 1996; 24: 1392-1394.
60. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282: 403-414.
61. Ellison RT, Horsburgh CR Jr, Curd J. Complement levels in patients with hepatic dysfunction. Dig. Dis. Sci. 1990; 35: 231-235.
62. Nguyen MH, Garcia RT, Simpson PW et al. Racial differences in effectiveness of alpha-feto protein for diagnosis of hepaticellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36: 410-417.
63. Fukuda Y, Nagura H, Asai J et al. Possible mechanisms of elevation of serum secretory immunoglobulin A in liver disease. Am. J. Gastroenterol. 1986; 81: 315-324.
64. Boden G, Cox Jr C. Carbohydrate metabolism. In: Rodes J, Benhamou JP, Blei A, Reichen J, Rizzetto M, eds. Oxford Textbook of Clinical Hepatology, 3rd edn. London: Wiley Blackwell, 2007, p. 129-133.
65. Schneeweiss B, Graninger W, Ferenci P et al. Energy metabolism in patients with acute and chronic liver disease. Hepatology 1990; 11: 387-393.
66. Zoli M, Magalotti D, Bianchi G et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 1999; 28: 29-33.
67. Dolle ME, Vijg J. Genome dynamics in aging mice. Genome Research 2002; 11: 1732-1738.
68. Fabbri A, Marchesini G, Bianchi G et al. Kinetics of hepatic amino-nitrogen conversion in ageing man. Liver 1994; 14: 288-294.
69. Schmucker DL. Age-related changes in liver structure and function: implications for disease? Exp. Gerontol. 2005; 40: 650-659.
70. Le Couteur DG, Warren A, Cogger VC et al. Old age and the hepatic sinusoid. Anat. Rec. 2008; 291: 672-683.
71. Parkinson A, Mudra DR, Johnson C et al. The effects of gender, ethnicity and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibilty in cultured human hepatocytes. Liver Toxicol. Appl. Pharmacol. 2004; 199: 193-209.